Basel Medical Group Ltd
BMGL0.720USD
-0.020-2.70%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
13.53MMarket Cap
LossP/E TTM
More Details of Basel Medical Group Ltd Company
Basel Medical Group Ltd is a holding company, which operates through its subsidiary, Basel Medical Group Pte. Ltd. It provides a wide spectrum of general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. Its orthopedic treatments and surgery include non-surgical treatments, such as medications, injections, splinting and physiotherapy, and surgical orthopedic procedures, including minimally invasive treatments for complex surgeries. Its rehabilitative therapy provides in-house physiotherapy treatments, including post-surgery rehabilitation, as well as sports therapy. Its neurosurgical care covers treatments involving spinal and brain conditions, from headaches and brain tumors to spinal issues, aneurysms and strokes. It also specializes in diagnostic imaging and outpatient care.
Basel Medical Group Ltd Info
Ticker SymbolBMGL
Company nameBasel Medical Group Ltd
IPO dateFeb 25, 2025
CEOChhoa (Yen Feng)
Number of employees77
Security typeOrdinary Share
Fiscal year-endFeb 25
Address600 North Bridge Road, #12-02/03
City
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountrySingapore
Postal code188778
Phone6562919188
Websitehttps://www.baselmedical.com
Ticker SymbolBMGL
IPO dateFeb 25, 2025
CEOChhoa (Yen Feng)
Company Executives of Basel Medical Group Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Boon Chye Tan
Mr. Boon Chye Tan
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Keng Leong (Raymond) Fung
Mr. Keng Leong (Raymond) Fung
Chairman of the Board
Chairman of the Board
--
--
Ms. Jianing Lu
Ms. Jianing Lu
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Dr. Yen Feng (Darren) Chhoa, M.D.
Dr. Yen Feng (Darren) Chhoa, M.D.
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Tony Chen
Mr. Tony Chen
Independent Director
Independent Director
--
--
Mr. Paul D. Freudenthaler, CPA
Mr. Paul D. Freudenthaler, CPA
Independent Director
Independent Director
--
--
Mr. Kwek Yoon Soong
Mr. Kwek Yoon Soong
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Boon Chye Tan
Mr. Boon Chye Tan
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Keng Leong (Raymond) Fung
Mr. Keng Leong (Raymond) Fung
Chairman of the Board
Chairman of the Board
--
--
Ms. Jianing Lu
Ms. Jianing Lu
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Dr. Yen Feng (Darren) Chhoa, M.D.
Dr. Yen Feng (Darren) Chhoa, M.D.
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Tony Chen
Mr. Tony Chen
Independent Director
Independent Director
--
--
Mr. Paul D. Freudenthaler, CPA
Mr. Paul D. Freudenthaler, CPA
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 24
Updated: Mon, Nov 24
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Rainforest Capital VCC
54.32%
Citadel Advisors LLC
0.49%
Morgan Stanley & Co. LLC
0.40%
Marex Group plc
0.31%
Virtu Americas LLC
0.18%
Other
44.29%
Shareholders
Shareholders
Proportion
Rainforest Capital VCC
54.32%
Citadel Advisors LLC
0.49%
Morgan Stanley & Co. LLC
0.40%
Marex Group plc
0.31%
Virtu Americas LLC
0.18%
Other
44.29%
Shareholder Types
Shareholders
Proportion
Corporation
54.32%
Research Firm
0.58%
Hedge Fund
0.49%
Investment Advisor
0.47%
Investment Advisor/Hedge Fund
0.04%
Other
44.10%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
14
296.50K
0.70%
--
2025Q3
14
296.50K
0.70%
+165.18K
2025Q2
6
124.34K
0.00%
+124.34K
2025Q1
5
12.74M
67.81%
+12.74M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Rainforest Capital VCC
10.17M
54.16%
+10.17M
--
Feb 25, 2025
Marex Group plc
13.92K
0.07%
+13.92K
--
Jun 30, 2025
Virtu Americas LLC
16.18K
0.09%
+16.18K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
6.97K
0.04%
--
--
Aug 31, 2025
UBS Financial Services, Inc.
5.64K
0.03%
+5.64K
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Basel Medical Group Ltd?
The top five shareholders of Basel Medical Group Ltd are:
Rainforest Capital VCC holds 10.17M shares, accounting for 54.16% of the total shares.
Marex Group plc holds 13.92K shares, accounting for 0.07% of the total shares.
Virtu Americas LLC holds 16.18K shares, accounting for 0.09% of the total shares.
Geode Capital Management, L.L.C. holds 6.97K shares, accounting for 0.04% of the total shares.
UBS Financial Services, Inc. holds 5.64K shares, accounting for 0.03% of the total shares.
Rainforest Capital VCC holds 10.17M shares, accounting for 54.16% of the total shares.
Marex Group plc holds 13.92K shares, accounting for 0.07% of the total shares.
Virtu Americas LLC holds 16.18K shares, accounting for 0.09% of the total shares.
Geode Capital Management, L.L.C. holds 6.97K shares, accounting for 0.04% of the total shares.
UBS Financial Services, Inc. holds 5.64K shares, accounting for 0.03% of the total shares.
What are the top three shareholder types of Basel Medical Group Ltd?
The top three shareholder types of Basel Medical Group Ltd are:
Rainforest Capital VCC
Citadel Advisors LLC
Morgan Stanley & Co. LLC
Rainforest Capital VCC
Citadel Advisors LLC
Morgan Stanley & Co. LLC
How many institutions hold shares of Basel Medical Group Ltd (BMGL)?
As of 2025Q4, 14 institutions hold shares of Basel Medical Group Ltd, with a combined market value of approximately 296.50K, accounting for 0.70% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.
What is the biggest source of revenue for Basel Medical Group Ltd?
In --, the -- business generated the highest revenue for Basel Medical Group Ltd, amounting to -- and accounting for --% of total revenue.
